Literature DB >> 11720744

Lung tumor markers of cytokeratin origin: an overview.

G Buccheri1, D Ferrigno.   

Abstract

Lung tumor markers fall into several categories including oncofetal proteins, structural proteins and their fragments, enzymes, membrane antigens, peptide and non-peptide hormones. Cytokeratins (CK) are well known structural proteins whose degradation gives rise to soluble fragments, measurable in the blood of patients and capable of cancer marking. Among them, Tissue Polypeptide Antigen (TPA), Tissue Polypeptide-Specific Antigen (TPS) and Cytokeratin-19-Fragments (Cyfra 21-1) are the most studied CK fragments' complexes. This article will review biological characteristics and clinical properties of these substances, emphasizing as their concentration in the peripheral blood might reflect the mass of tumor, the rate of cancer cell lysis, and other potentially unfavorable tumor characteristics. Assaying the concentration of CK fragments in the blood is an easy and effective way to assess lung cancer and monitor its clinical evolution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720744     DOI: 10.1016/s0169-5002(01)00347-6

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  14 in total

1.  LC/LC-MS/MS of an innovative prostate human epithelial cancer (PHEC) in vitro model system.

Authors:  John D Lapek; James L McGrath; William A Ricke; Alan E Friedman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-03       Impact factor: 3.205

Review 2.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 3.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response.

Authors:  Juan Wang; Ning Zhang; Baosheng Li; Zhongtang Wang; Hongfu Sun; Yan Yi; Wei Huang
Journal:  Tumour Biol       Date:  2011-03-16

5.  Using protein microarray as a diagnostic assay for non-small cell lung cancer.

Authors:  Li Zhong; Giovanna E Hidalgo; Arnold J Stromberg; Nada H Khattar; James R Jett; Edward A Hirschowitz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

6.  Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.

Authors:  Fengsheng Chen; Xi Luo; Jinbiao Zhang; Yang Lu; Rongcheng Luo
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

7.  Significance of tumor markers in lung cancer.

Authors:  P P Mumbarkar; A S Raste; M S Ghadge
Journal:  Indian J Clin Biochem       Date:  2006-03

8.  Diagnostic potential of extracellular vesicle-associated microRNA-10b and tumor markers for lung adenocarcinoma.

Authors:  Guangda Yuan; Hongya Xie; Tengteng Wei; Donglin Zhu; Chuanyu Zhang; Yong Yang
Journal:  Oncol Lett       Date:  2021-06-23       Impact factor: 2.967

9.  Proteomic analysis of lamellar bodies isolated from rat lungs.

Authors:  Pengcheng Wang; Narendranath Reddy Chintagari; Jeyaparthasarathy Narayanaperumal; Sahlu Ayalew; Steven Hartson; Lin Liu
Journal:  BMC Cell Biol       Date:  2008-06-24       Impact factor: 4.241

10.  The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types.

Authors:  Haiqing Chen; Fangqiu Fu; Yue Zhao; Haoxuan Wu; Hong Hu; Yihua Sun; Yawei Zhang; Jiaqing Xiang; Yang Zhang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.